Matches in Wikidata for { <http://www.wikidata.org/entity/Q104131927> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- Q104131927 description "2020 ވަނަ އަހަރުގެ ޑިސެމްބަރުމަހުގެ 4ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ސައިންޓިފިކް ލިޔުމެއް" @default.
- Q104131927 description "article scientifique publié en 2020" @default.
- Q104131927 description "artículu científicu espublizáu n'avientu de 2020" @default.
- Q104131927 description "scientific article published on 04 December 2020" @default.
- Q104131927 description "wetenschappelijk artikel" @default.
- Q104131927 description "наукова стаття, опублікована 4 грудня 2020" @default.
- Q104131927 name "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 name "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 name "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 type Item @default.
- Q104131927 label "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 label "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 label "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 prefLabel "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 prefLabel "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 prefLabel "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 P1433 Q104131927-4BA44AB4-E2DF-411B-B449-617AA56C7DDA @default.
- Q104131927 P1476 Q104131927-1279A953-0659-41BE-95C8-706A5BE92070 @default.
- Q104131927 P2093 Q104131927-150A6593-3E0D-4CD1-A58B-4300F3B358F8 @default.
- Q104131927 P2093 Q104131927-15D709CC-D122-488A-9C28-8341B2E0EEC1 @default.
- Q104131927 P2093 Q104131927-2FC617B5-8C4D-4898-BBCD-F4E1AF3CAD15 @default.
- Q104131927 P2093 Q104131927-3534E1FB-3D10-4987-8E26-7FD584CC217A @default.
- Q104131927 P2093 Q104131927-355E1D11-1055-4935-8397-A74425CBD042 @default.
- Q104131927 P2093 Q104131927-465F3294-1E87-4152-9113-44583F73C7CB @default.
- Q104131927 P275 Q104131927-fe1f6508-1b4f-452b-83ee-a8de585e957a @default.
- Q104131927 P31 Q104131927-1417B1B2-1619-432F-BD68-984A17EE8C1F @default.
- Q104131927 P356 Q104131927-A1F8C7B2-0904-4402-8C8C-A7E69F0318F5 @default.
- Q104131927 P433 Q104131927-7EF51716-19D9-432D-91FA-545C1D3856B1 @default.
- Q104131927 P478 Q104131927-1DE3F807-8EF9-4F69-8E39-D47C3976B931 @default.
- Q104131927 P50 Q104131927-D6CEDBB2-90EA-4ACE-A35F-1B72AB1C8B1D @default.
- Q104131927 P577 Q104131927-398AED5C-2DA7-4C6E-8C4C-4C938CF253AA @default.
- Q104131927 P6216 Q104131927-d7c3701f-851f-44c5-b074-86644dc1b126 @default.
- Q104131927 P698 Q104131927-27B2108F-ACA1-4FC9-AF5C-CC4986776E39 @default.
- Q104131927 P921 Q104131927-271259EE-A5DB-464E-804C-2C51A738C823 @default.
- Q104131927 P921 Q104131927-DC161B7D-28B0-424E-8236-FE971A9207FE @default.
- Q104131927 P932 Q104131927-DA971302-F850-4827-B499-4A66960C4766 @default.
- Q104131927 P356 CANCERS12123648 @default.
- Q104131927 P698 33291810 @default.
- Q104131927 P1433 Q27722963 @default.
- Q104131927 P1476 "A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ≥1% Metastatic NSCLC" @default.
- Q104131927 P2093 "Andrew Frederickson" @default.
- Q104131927 P2093 "Balazs Halmos" @default.
- Q104131927 P2093 "Bilal Piperdi" @default.
- Q104131927 P2093 "Kristel Vandormael" @default.
- Q104131927 P2093 "Ralph Insinga" @default.
- Q104131927 P2093 "Thomas Burke" @default.
- Q104131927 P275 Q20007257 @default.
- Q104131927 P31 Q13442814 @default.
- Q104131927 P356 "10.3390/CANCERS12123648" @default.
- Q104131927 P433 "12" @default.
- Q104131927 P478 "12" @default.
- Q104131927 P50 Q64880158 @default.
- Q104131927 P577 "2020-12-04T00:00:00Z" @default.
- Q104131927 P6216 Q50423863 @default.
- Q104131927 P698 "33291810" @default.
- Q104131927 P921 Q13896859 @default.
- Q104131927 P921 Q3658562 @default.
- Q104131927 P932 "7762014" @default.